Estados Unidos · Agencias y tiempo real · Business Wire

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Publicado por Business Wire · Estados Unidos hace 10 h

PharmaEssentia’s blood cancer treatment, ropeginterferon alfa-2b (Ropeg), has secured approvals for essential thrombocythemia (ET) in Taiwan, Japan, the ...

Leer el artículo completo en Business Wire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.businesswire.com)

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

También te puede interesar

100% Bearing Free: Maglev Enables 6-DOF with Zero Contact, Applications in Hybrid Bonding, Wafer Metrology

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot

Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

Compartir

También te puede interesar

100% Bearing Free: Maglev Enables 6-DOF with Zero Contact, Applications in Hybrid Bonding, Wafer Metrology

8 innovative gifts meant to change up how we drive, cook, sleep and more

Rethinking AI in Enterprise Intelligence

Global Financial News from MT Newswires Now Live in Microsoft Copilot